TET1, 2, and 3 and IDH1 and IDH2 were measured in CD19+ CLL samples (mean purity 99.2%, range 97.5–99.9) and compared with the normal CD19+ cells. This evidence concerns the gene TET1 and B-cell chronic lymphocytic leukemia.